iShares Core S&P Total U.S. Stock Market ETF (ITOT)
149.16
+0.00 (0.00%)
NYSE · Last Trade: Jan 5th, 5:33 AM EST
Detailed Quote
| Previous Close | 149.16 |
|---|---|
| Open | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 105.00 - 150.91 |
| Volume | 1 |
| Market Cap | 784.73M |
| Dividend & Yield | 1.656 (1.11%) |
| 1 Month Average Volume | 2,512,940 |
Chart
News & Press Releases
With similar holdings and costs, the real differences between these two broad-market ETFs come down to scale and trading activity.
Via The Motley Fool · January 4, 2026
Explore how differences in fund size, holdings, and sector weightings set these two low-cost ETFs apart for investors seeking total stock market exposure.
Via The Motley Fool · January 4, 2026
Explore how differences in sector exposure and dividend focus shape the risk and income profiles of these two popular ETFs.
Via The Motley Fool · January 3, 2026
ONDS Stock Rises Following Acquisition Of Israel-Based Sentry CSstocktwits.com
Via Stocktwits · November 4, 2025
KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreementstocktwits.com
Via Stocktwits · October 24, 2025
Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Updatestocktwits.com
Via Stocktwits · October 2, 2025
The company announced on Friday that it expects FY2026 revenue in the $450 million to $475 million range.
Via Stocktwits · January 2, 2026
Better Broad-Market ETF: ITOT vs. SPTMfool.com
Fund size, stock coverage, and trading flexibility set these two ultra-low-cost ETFs apart for investors prioritizing scale and liquidity.
Via The Motley Fool · December 21, 2025
Coty has sold its remaining 25.8% stake in Wella to KKR-managed capital accounts and investment affiliates for an upfront cash payment of $775 million.
Via Stocktwits · December 19, 2025
This ETF is proof that broad exposure doesn't have to mean sacrificing gains.
Via The Motley Fool · November 24, 2025
VTI and ITOT offer nearly identical market exposure, yet a few subtle differences set them apart. This piece highlights what those differences mean and how to decide which fund fits your long-term plan.
Via The Motley Fool · November 19, 2025
The company has announced that it has now received the only regulatory approval required and expects to close the acquisition on schedule, in line with its stated target for the fourth quarter of calendar year 2025.
Via Stocktwits · November 12, 2025
Nearly half of ETF investors could go all-ETF within five years, Schwab says. Here's how they're building portfolios with funds like ITOT, BND, and XLK.
Via Benzinga · November 8, 2025
Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.
Via Stocktwits · October 23, 2025
The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.
Via Stocktwits · September 29, 2025
The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale.
Via Stocktwits · September 24, 2025
U.S. inflation ticked up to 2.9% in August, fueling Fed caution. Discover the ETFs that could offer stability and upside in a sticky inflation environment.
Via Benzinga · September 12, 2025
Super Micro Computer will help AI infrastructure provider Digi Power X expand its ARMS 200 data center platform in Alabama.
Via Stocktwits · July 29, 2025
Trump met with Canadian PM Carney to discuss strained relations at G7 summit. Talks were optimistic and a deal is possible within weeks.
Via Benzinga · June 18, 2025
The proceeds from the purchase agreement are expected to be used for working capital and general corporate purposes.
Via Stocktwits · June 12, 2025
A diversified approach, using exchange-traded funds in US stocks, international equities, and bonds, helps investors weather ongoing market volatility.
Via MarketBeat · March 16, 2025

The markets are setting up for a big test.
Via Talk Markets · February 28, 2025

Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects.
Via Stocktwits · February 12, 2025

Via The Motley Fool · February 1, 2025

Super Micro’s stock ended 2024 with a modest gain of 7.2%, as the front-end-loaded gains for the year offset the weakness in the second half amid multiple headwinds.
Via Stocktwits · January 16, 2025
